Tom3 schreef op 1 juli 2024 21:31:
Extreem verhelderende analyse door dhr Bautz vandaag verschenen:
finance.yahoo.com/news/arwr-moving-pl..."While the full dataset will be presented at a medical conference later this year, we feel it is still worthwhile to do a quick comparison of the results of the PALISADE study with those for Ionis Pharmaceuticals’ olezarsen. Ionis recently reported that the NDA for olezarsen for the treatment of FCS was accepted for Priority Review with a PDUFA date of December 19, 2024. The results from the Phase 3 trial of olezarsen in FCS were recently published in The New England Journal of Medicine (Witztum et al., 2024).
Since Arrowhead only released a limited amount of data it is difficult to do a full comparison of the results to those for olezarsen, however we believe that the following graphs showing the mean change over time in triglyceride levels for each study demonstrate what we believe to be is superior efficacy for plozasiran in decreasing triglycerides (with dosing just once every three months compared to olezarsen dosing once a month). "